Physician profile
James Starr
NPI 1942567060
$8,864.76
in general payments reported to CMS, 2019-2025
51 companies · $2,202 in 2025
The $2,202 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,633 · 2020: $266 · 2021: $152 · 2022: $630 · 2023: $1,590 · 2024: $2,392 · 2025: $2,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,183.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,679.00 | 2019-2025 | Ubrelvy, Botox, Duopa |
| Medtronic USA, INC. | $899.15 | 2019 | |
| Ucb, INC. | $777.09 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Pfizer INC. | $577.53 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $478.10 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Mdd US Operations, LLC | $471.94 | 2024-2025 | Gocovri, Qelbree |
| Lundbeck LLC | $322.77 | 2019-2025 | Vyepti |
| Neurocrine Biosciences, INC. | $276.15 | 2023-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $255.09 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Sk Life Science, INC. | $237.58 | 2022-2025 | |
| Argenx US, INC. | $222.98 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $200.20 | 2019-2025 | Nuplazid |
| Lilly USA, LLC | $193.61 | 2019-2025 | Emgality, Amyvid |
| Kyowa Kirin, INC. | $168.66 | 2019-2024 | Nourianz |
| Allergan, INC. | $161.07 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Starr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.